Asuragen Launches Signature(R) LTx (Leukemia Translocation Panel) Globally.AUSTIN, Texas -- Asuragen, Inc. announced today the global launch of Signature[R] LTx (Leukemia Translocation translocation /trans·lo·ca·tion/ (trans?lo-ka´shun) the attachment of a fragment of one chromosome to a nonhomologous chromosome. Abbreviated t. Panel), a multiplexed reverse transcription PCR PCR polymerase chain reaction.
polymerase chain reaction
Polymerase chain reaction (PCR) (RT-PCR RT-PCR
reverse transcriptase-polymerase chain reaction. See PCR1. ) assay that detects nine common leukemia-associated translocations. The assay is performed on a Luminex cytometer using a multi-probe liquid bead array method. The liquid bead array format provides comprehensive information in a single well, providing efficiency and cost benefits to the laboratory.
The product was first launched in the United States late 2005, and is currently utilized by hospitals and cancer centers throughout the United States. The Signature LTx (RUO RUO Research Use Only
RUO Reference Unbundling Offer
RUO Run Ultima Online (emulator program)
RUO Resident Unit Officer ) panel is utilized for the rapid detection and identification of the fusion transcripts from common chromosome translocations and abnormalities associated with CML 1. CML - A query language.
["Towards a Knowledge Description Language", A. Borgida et al, in On Knowledge Base Management Systems, J. Mylopoulos et al eds, Springer 1986].
2. CML - Concurrent ML. , AML AML - A Manufacturing Language , APL, and ALL. "The Signature LTx panel is more sensitive than standard karyotype and FISH analysis, and because it is highly multiplexed, eliminates the need for analysis on numerous assays and platforms," said Dr. Tim Stenzel, Vice President R & D, and Chief Medical Officer, Asuragen, Inc.
The Signature[R] LTx (RUO) product is available immediately to laboratories throughout the world. This product launch marks the continued globalization of the Signature[R] product portfolio, including reagents for cystic fibrosis and Ashkenazi Carrier Panel.
About Asuragen, Inc.
Asuragen is a fully integrated diagnostic reagent company and molecular biology service provider, focused on molecular oncology and genetic diseases, with emphasis on microRNA (miRNA). Asuragen's current diagnostic product portfolio consists of Signature[R] Genetic Testing and Oncology Testing products as well as industry leading controls and standards engineered using its patented Armored RNA RNA: see nucleic acid.
in full ribonucleic acid
One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic [R] technology. Asuragen is empowered with a high level of scientific expertise and assay development along with a well developed business infrastructure, GLP See gateway location protocol. testing services and an established cGMP manufacturing facility that allows it to span the spectrum of discovery, testing, production and commercialization. Asuragen is dedicated to developing new technologies that will become cutting edge clinical products. More information is available at the Company's website: www.asuragen.com.
In addition, Asuragen has a miRNA therapeutics program which was recently spun off into a separate entity called Mirna Therapeutics. More information on Mirna Therapeutics is available at www.mirnatherapeutics.com.